Radiation Oncology Advances-..
R$ 1.410,92
até
4x
de
R$ 352,73
sem juros
ou R$ 1.340,37
via Pix
Adicionar ao carrinho
Disponibilidade: 45 dias úteis
Estoque: 176 unidades
-
- 1x de R$ 1.410,92 sem juros
- 2x de R$ 705,46 sem juros
- 3x de R$ 470,30 sem juros
- 4x de R$ 352,73 sem juros
-
R$ 1.340,37
-
R$ 1.410,92
from combining radiation with a molecular targeted agent - namely cetuximab, a recombinant mouse/human chimeric monoclonal antibody against the Epidermal Growth Factor (EGF) receptor [4] Astsaturov, Cohen and Harari present a more indepth review of the biology of the EGF Receptor and its signaling pathway in Chap. 7 as a potential target in combination with fractionated radiotherap y for head and neck squamous cell carcinoma (HNSCC). A flurry of agents are under de velopment for targeting EGFR and in March 2006, the US Food and Drugs Administration approved cetuximab combined with radiation as a primary treatment option for patients with loco-regionally advanced HNSCC in whom chemoradiation therapy is deemed not to be an option. While blocking the EGF pathway during fractionated radiotherapy may seem an obvious strategy [5], the rationale for combining antiangiogenic and antivascular targeting agents with radiation may be less intuitive. However, recent research shows that there are several reasons why this could result in a therapeutic gain in practice. Chapter 8 is a review of this rapidly expanding field by Citrin and Camphausen. Targeted agents combined with radiation may offer new opportunities in the treatment of central nervous system malignancies, a tumor type where the outlook remains poor despite some recent progress [6]. Current attempts to overcome rad- tion resistance in these tumors on the basis of an improved understanding of their molecular biology are the topic of Chap. 9 by Chakravarti and Palanichamy.
| ISBN | 9780387367439 |
| Autor(a) | Bentzen, Søren M. |
| Editora | Springer Publishing |
| Ano de edição | 2007 |
| Páginas | 336 |
| Acabamento | Capa Dura |
Produtos relacionados
-
Innovations In Radiation Oncology-..R$ 456,42R$ 365,14até 4x de R$ 91,28 sem jurosou R$ 346,88 via Pix20% Desconto -
Controversies In Radiation Oncology-..R$ 1.825,92até 4x de R$ 456,48 sem jurosou R$ 1.734,62 via Pix
Categorias
Pague com
Selos
MYRE EDITORA, COMERCIALIZADORA, IMPORTADORA E DISTRIBUIDORA LTDA - CNPJ: 50.295.718/0001-20 © Todos os direitos reservados. 2026
